CBABiopharmaUS–China
Round Table Discussion at the CBA 31st Annual Conference
Chinese Biopharmaceutical Association, USA (CBA) · July 2026
Co-authored with Frank Chen, PhD, EMBA, Johns Hopkins University Carey Business School
Leaders from biotech, pharma, finance, academia, and policy compared the US and China as two different paths through biopharma's innovation gap. The summary covers regulatory pathways, pricing and reimbursement, and why the US market stays central for global biopharma.
“For the future biopharma industry, the winning equation is not only relevant to China biotech, but to global innovators: strong science, disciplined execution, cross-market trust, and a shared commitment to improving health.”From the roundtable summary
Read on CBA ↗